The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCAT 2023 | The current landscape of SCD treatment
Miguel Brito, PhD, Lisbon School of Health Technology, Lisbon, Portugal, presents the findings of an analysis of currently available pharmacological interventions for treating sickle cell disease (SCD), with the primary finding being that hydroxyurea is the most important treatment currently available. Dr Brito emphasizes the need for the development of new therapies, as very few drugs are approved for the disease at present, as well as the need to ensure access to hydroxyurea is improved in low- to middle-income countries, such as Angola. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
